Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1 - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Nature Communications Year : 2020

Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1

Abstract

Immune checkpoint inhibitors (ICIs) have dramatically modified the prognosis of several advanced cancers, however many patients still do not respond to treatment. Optimal results might be obtained by targeting cancer cell metabolism to modulate the immunosuppressive tumor microenvironment. Here, we identify sphingosine kinase-1 (SK1) as a key regulator of anti-tumor immunity. Increased expression of SK1 in tumor cells is significantly associated with shorter survival in metastatic melanoma patients treated with anti-PD-1. Targeting SK1 markedly enhances the responses to ICI in murine models of melanoma, breast and colon cancer. Mechanistically, SK1 silencing decreases the expression of various immunosuppressive factors in the tumor microenvironment to limit regulatory T cell (Treg) infiltration. Accordingly, a SK1-dependent immunosuppressive signature is also observed in human melanoma biopsies. Altogether, this study identifies SK1 as a checkpoint lipid kinase that could be targeted to enhance immunotherapy.
Fichier principal
Vignette du fichier
s41467-019-14218-7.pdf (1.92 Mo) Télécharger le fichier
Origin : Publication funded by an institution
Loading...

Dates and versions

inserm-02492179 , version 1 (26-02-2020)

Licence

Attribution

Identifiers

Cite

Caroline Imbert, Anne Montfort, Marine Fraisse, Elie Marcheteau, Julia Gilhodes, et al.. Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1. Nature Communications, 2020, 11 (1), pp.437. ⟨10.1038/s41467-019-14218-7⟩. ⟨inserm-02492179⟩
112 View
86 Download

Altmetric

Share

Gmail Facebook X LinkedIn More